603590 Beijing Konruns Pharmaceutical
- 21.47
- +0.05+0.23%
Beijing Konruns Pharmaceutical News
Announcement of Resolutions of the 9th Meeting of the Fourth Board of Supervisors of Kangchen Pharmaceutical
Kangchen Pharmaceutical\'s announcement on renewing the employment of an accounting firm
Kangchen Pharmaceutical\'s special report on the storage and actual use of funds raised in the 2024 semi-year
Announcement of Resolutions of the 11th Meeting of the Fourth Board of Directors of Kangchen Pharmaceutical
Announcement on using part of the idle raised funds for cash management redemption by Beijing Konruns Pharmaceutical
Beijing Konruns Pharmaceutical: Announcement from Beijing Konruns Pharmaceutical on traditional Chinese medicine innovative drug ZY5301 clinical research results being featured in the sub-journal of JAMA.
Announcement of Resolution of the Tenth Meeting of the Fourth Board of Directors of Beijing Konruns Pharmaceutical.
Announcement of the resolution of the Eighth Meeting of the Fourth Supervisory Board of Beijing Konruns Pharmaceutical.
Special instruction on the auditor's report with emphasis of matter paragraph and unqualified opinion issued by HuaXing CPA Firm for the 2023 financial statements of Beijing Konruns Pharmaceutical Co., Ltd. (revised version).
Supplementary Announcement on Special Explanation of Non-standard Audit Opinion on the 2023 Annual Financial Statements of Beijing Konruns Pharmaceutical Co., Ltd.
Regarding the unqualified opinion with emphasis on matters related to the audit report of Beijing Konruns Pharmaceutical Co., Ltd. for the year 2023, the relevant issues have been eliminated in the audit report.
The board of directors of Beijing Konruns Pharmaceutical emphasized the special instructions on the elimination of the matters involved in the section of the audit report on the 2023 annual report.
Announcement of the Resolution of the 9th meeting of the 4th session of the board of directors of Beijing Konruns Pharmaceutical.
The board of supervisors of Beijing Konruns Pharmaceutical has opinions on the special statement concerning the elimination of matters related to the emphasis section of the audit report on the 2023 annual report by the board of directors.
Announcement of the resolution of the 7th meeting of the 4th supervisor meeting of Beijing Konruns Pharmaceutical.
Beijing Konruns Pharmaceutical Investor Relations Activity Report - April to June 2024
Special examination opinion of Beijing Guofeng Law Firm on the differentiated dividend issue of Beijing Konruns Pharmaceutical Co., Ltd.
Announcement from Beijing Konruns Pharmaceutical regarding the holding of the 2023 annual and Q1 2024 performance briefing.
Kangchen Pharmaceutical's Announcement on Using Part of Idle Raised Funds for Cash Management and Redemption
Kangchen Pharmaceutical's announcement on opening a special settlement account for fund-raising and wealth management products
Analysis
Price Target
No Data
